Skip to content

纽维生物

US · NUVB #2898 按市值排名 上市于 1970
4.45 -0.30 -6.32%
实时 - 追踪5344个代码 - 心跳于525秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量增加了1家。
  • 机构持股总比例下降了0.1个百分点。

机构持股

机构持股比例
67.05% -0.13pp
机构数量
284 +1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund43.31%
Individual/Insider17.52%
VC/PE Fund10.16%
Hedge Fund8.62%
Public Company2.07%
Family Office/Trust1.35%
Private Company1.11%
Government Pension Fund0.36%
Other15.43%

主要股东 截至 2025-06-16

David Hung 17.17% · 60.28M 股
FMR 14.88% · 52.23M 股
BlackRock 7.87% · 27.63M 股
Decheng Capital LLC 7.39% · 25.95M 股
Vanguard Capital Management, LLC 3.90% · 13.70M 股
Omega Fund Management, LLC 2.30% · 8.08M 股
Laurion Capital Management LP 2.23% · 7.82M 股
State Street Global Advisors 2.10% · 7.37M 股
Geode Capital Management, LLC 1.78% · 6.24M 股
Duquesne Family Office LLC 1.29% · 4.54M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 34次买入 · 16次卖出

姓名职务持股比例
David Hung Chief Executive Officer 17.17%
William Vernon Independent Director 0.09%
Kathryn Falberg Independent Director 0.07%
Robert Mashal Director 0.06%
Kim Blickenstaff Independent Director 0.05%
Colleen Sjogren Chief Commercial Officer 0.02%
Philippe Sauvage Chief Financial Officer 0.02%
Kerry Wentworth Chief Regulatory Officer 0.02%
Stacy Markel Chief Human Resources Officer 0.01%
David Hanley Chief Technical Operations Officer 0.01%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-08-18 Gary Hattersley Chief Scientific Officer Derivative Exercise and Sale -100,000 $1.87–7.09
2026-07-14 Philippe Sauvage Chief Financial Officer Derivative Exercise and Retained +40,000 $1.97–2.17
2026-06-22 Kerry Wentworth Chief Regulatory Officer Derivative Exercise and Sale -63,000 $2.93–6.02
2026-06-22 Stacy Markel Chief Human Resources Officer Derivative Exercise and Sale -125,000 $1.74–6.03
2026-06-22 Philippe Sauvage Chief Financial Officer Derivative Exercise and Sale -47,668 $2.17–6.01
2026-06-08 Robert Mashal Director Open Market Acquisition +25,000 $4.73
2026-05-20 Kathryn Falberg Independent Director Other Derivative Acquisition +123,397 $4.79
2026-05-20 Kim Blickenstaff Independent Director Other Derivative Acquisition +123,397 $4.79
2026-05-20 Robert Bazemore Lead Independent Director Other Derivative Acquisition +123,397 $4.79
2026-05-20 Robert Mashal Director Other Derivative Acquisition +123,397 $4.79
2026-05-20 William Vernon Independent Director Other Derivative Acquisition +123,397 $4.79
2026-05-20 Xiangmin Cui Director Other Derivative Acquisition +123,397 $4.79
2026-04-16 Kerry Wentworth Chief Regulatory Officer Derivative Exercise and Sale -36,750 $2.93–5.01
2026-04-16 Dongfang Liu -- Derivative Exercise and Sale -50,000 $1.94–5.02
2026-04-05 Kerry Wentworth Chief Regulatory Officer Derivative Exercise and Sale -200,000 $1.87–4.52
2026-02-26 David Hung Chief Executive Officer Other Derivative Acquisition +1,995,012 $5.91
2026-02-26 Kerry Wentworth Chief Regulatory Officer Other Derivative Acquisition +748,130 $5.91
2026-02-26 Xiangmin Cui Director Other Derivative Acquisition +76,923 $5.91
2026-02-26 Stacy Markel Chief Human Resources Officer Other Derivative Acquisition +748,130 $5.91
2026-02-26 Gary Hattersley Chief Scientific Officer Other Derivative Acquisition +748,130 $5.91

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:21 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

纽维生物 讨论区 0 条评论

发表评论